基于五种胃特异性循环生物标志物的血清学活检用于胃癌风险评估:一项多阶段研究
在中国一项基于人群的筛查项目中,对12112名接受血清学和胃镜筛查并有前瞻性随访的参与者进行多阶段研究。五种生物标志物联合识别癌前病变的C统计量为0.803,优于传统危险因素;血清学活检评分越高,随访期间胃癌风险越高。
要点
- 五种胃特异性循环生物标志物联合可识别需进一步胃镜检查的高危个体。
- 基于五种标志物的血清学活检评分越高,随访期间胃癌风险越高(趋势P<0.001)。
- 低PGI和低PGI/II比值与胃癌风险升高相关,G-17与胃癌风险呈J形关联。
核心结论
- 由五种胃特异性循环生物标志物组成的血清学活检可用于识别需进一步诊断性胃镜检查的高危个体,并对胃癌发生风险进行分层,从而指导针对性筛查和精准预防。
研究设计与样本
- 在中国一项同时使用血清学和胃镜的持续性人群筛查项目中,纳入12112名有前瞻性随访的参与者,开展多阶段研究,包括横断面分析、随访分析和整合风险预测建模分析。
主要发现
- 横断面分析中,五种生物标志物(尤其是PGII、PGI/II比值和幽门螺杆菌血清阳性)与入组时癌前胃病变或胃癌的存在相关。
- 随访分析中,低PGI水平和低PGI/II比值与胃癌发生风险升高相关;低(<0.5 pmol/l)和高(>4.7 pmol/l)G-17水平均与胃癌发生风险升高相关,提示J形关联。
- 风险预测建模分析中,五种生物标志物联合识别入组时癌前病变的C统计量为0.803(95%CI=0.789-0.816),优于传统危险因素(C统计量从0.580提高到0.811,P<0.001)。
- 入组时基于五种生物标志物的较高血清学活检评分与随访期间较高的胃癌发生风险相关(趋势P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We aimed to assess a serological biopsy using five stomach-specific circulating biomarkers-pepsinogen I (PGI), PGII, PGI/II ratio, anti-Helicobacter pylori (H. pylori) antibody, and gastrin-17 (G-17)-for identifying high-risk individuals and predicting risk of developing gastric cancer (GC). METHODS: Among 12,112 participants with prospective follow-up from an ongoing population-based screening program using both serology and gastroscopy in China, we conducted a multi-phase study involving a cross-sectional analysis, a follow-up analysis, and an integrative risk prediction modeling analysis. RESULTS: In the cross-sectional analysis, the five biomarkers (especially PGII, the PGI/II ratio, and H. pylori sero-positivity) were associated with the presence of precancerous gastric lesions or GC at enrollment. In the follow-up analysis, low PGI levels and PGI/II ratios were associated with higher risk of developing GC, and both low (<0.5 pmol/l) and high (>4.7 pmol/l) G-17 levels were associated with higher risk of developing GC, suggesting a J-shaped association. In the risk prediction modeling analysis, the five biomarkers combined yielded a C statistic of 0.803 (95% confidence interval (CI)=0.789-0.816) and improved prediction beyond traditional risk factors (C statistic from 0.580 to 0.811, P<0.001) for identifying precancerous lesions at enrollment, and higher serological biopsy scores based on the five biomarkers at enrollment were associated with higher risk of developing GC during follow-up (P for trend <0.001). CONCLUSIONS: A serological biopsy composed of the five stomach-specific circulating biomarkers could be used to identify high-risk individuals for further diagnostic gastroscopy, and to stratify individuals' risk of developing GC and thus to guide targeted screening and precision prevention.
引用
- Tu H, Sun L, Dong X, et al. A Serological Biopsy Using Five Stomach-Specific Circulating Biomarkers for Gastric Cancer Risk Assessment: A Multi-Phase Study. Am J Gastroenterol. 2017. PMID: 28323271. doi:10.1038/ajg.2017.55
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。